EndPoints News: MPM and Longwood-backed Werewolf Therapeutics grabs $56 million to take tumors by night

November 20, 2019

Backed with the team from his last company, one of the key developers behind Keytruda has a new warchest in the race to bring immunotherapy into the tumor micro-environment.

Read the full story

EndPoints News

By Jason Mast

March 3, 2020

Designing conditionally activated immune stimulators that attack cancer cells

As seen in Nature Biopharma Dealmakers Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered Read More

December 17, 2019

Pittsburgh Business Times: UPMC Enterprises invests in immunotherapy startup

UPMC Enterprises is part of the investor group for a Massachusetts startup that focuses on immunotherapies, the types of treatments that Read More

December 13, 2019

Smart Business Dealmakers Pittsburgh: UPMC Enterprises Invests In Werewolf Therapeutics

UPMC Enterprises joined a Series A funding round of $56 million for Werewolf Therapeutics. The Cambridge, Massachusetts-based oncology biotherapeutics company is developing Read More

Share this article: